Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERCEPT-Lynch trial of mRNA-4194 in adults with Lynch syndrome
ISRCTN78380445Phase 2Recruiting
- Sponsor
- University of Oxford
- Start
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 2, randomised, open-label trial of mRNA-4194 in hereditary nonpolyposis colorectal cancer (HNPCC) (3 arms), sponsored by University of Oxford. Primary endpoints: Part 1 safety and tolerability, Part 1 determination of recommended dose(s) for expansion and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
mRNA-4194
03
Conditions
hereditary nonpolyposis colorectal cancer (HNPCC)
Beyond the preview
Go deeper on ISRCTN78380445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN78380445.